In clinical trials of patients with various types
of retinal diseases, including macular degeneration, diabetic retinopathy,
retinitis pigmentosa, and hemorrhagic and hypertensive retinopathy, all
persons given Flavay® showed significant improvement.
Licensed and sold for eye
health in France, the vascular protective activity of Flavay®
has been established by many significant studies.
Flavay® has been sold world-wide for vascular and eye health and
extensively tested in humans for more than 50 years. The vascular protective
activity of Flavay® has been established by many significant studies,
demonstrating several important ways in which Flavay® may protect
the vascular health of the eyes. Flavay® can protect the eyes from
free radical damage, support overall circulatory function, reinforce collagen
structures of the retina, enhance the eye’s ability to visually adapt
to different light environments, and protect the health of the eye and
retina.
Protecting the Smallest Blood Vessels
in the Eyes
Flavay® has been shown
to reduce pressure in ophthalmic membranes by preventing abnormal
leakage of fluids into the orbital cavity and tissues.
Our Customers Say: “I'm in my 80s and I've been taking 4 Flavay® every day for about 3 years now. I started taking Flavay® for glaucoma pain, but I no longer have any pain and I no longer need or take any glaucoma medication. In fact, according to my most recent ophthalmologist's visit, I no longer have any symptoms of glaucoma!”
—Ms. S. G.
The health of the eyes depends to a great extent on the integrity of
the fine vessels that supply blood to the area. Research shows that Flavay®
has the capacity to improve visual performance in various ways.
Flavay® actually strengthens collagen in vascular walls and capillaries
(the smallest vessels), making the vessels stronger and more elastic.
Flavay® alters the membrane receptor conformation of vascular walls,
reducing the damaging effects of the destructive enzymes elastase, collagenase
and hyaluronidase, by preventing them from attaching to and degrading
vascular walls. Flavay® further prevents destruction of vascular
walls by preventing the attachment to membranes of histamine and hyaluronidase,
both of which can decrease the strength of vessel walls. Thus, in addition
to preventing the root causes of vessel occlusion, Flavay® strengthens
vessels, thereby reducing the risk of a rupture or hemorrhage, and helping
to prevent and relieve vascular fragility.
In clinical trials of patients with various types of retinal diseases,
including macular degeneration, diabetic retinopathy, retinitis pigmentosa,
and hemorrhagic and hypertensive retinopathy, all persons given Flavay®
showed significant improvement following therapy. Flavay® has been
shown to reduce pressure in ophthalmic membranes by preventing abnormal
leakage of fluids into the orbital cavity and tissues.
Diabetic retinopathy is
one of the leading causes of blindness and any agent that can
help to stem the effects of retinopathy is of value.
Many clinical studies conducted
in Europe show that Flavay® greatly improved symptoms in
patients with diabetic retinopathies and maculopathies.
Our Customers Say:“After taking Flavay® and Flavay Plus® [for about four months] my vision is more clear, so much so that I can drive a car and even read a newspaper. Macular degeneration may have etched areas of my retina and I still have to move my eyes around to find spots where I can see the best-but even that has improved a little. I can hardly believe my improvement. I'm astounded that something so simple, strengthening the capillaries in the eyes, has meant so much improvement.”
—retired medical doctor
Diabetic Retinopathy
Retinopathy is especially a problem for diabetics, who suffer from greatly
increased capillary permeability in their eyes. The vascular wall and
eye lens of a diabetic are especially aggravated due to the nature of
the disease.
There are basically two types of diabetic retinopathy, the background
type and the proliferative type. The background type is characterized
by microaneurisms (small sacs which develop as a result of excessive vascular
dilation), intraretinal hemorrhages, yellowish waxy exudates, and swelling
of the macula. The proliferative type is characterized by the development
of new vessels in the retina and disk, proliferation of fibrous tissue,
vitreous hemorrhage and detachment of the retina. In either case, diabetic
retinopathy is one of the leading causes of blindness, and any agent that
can help to stem the effects of retinopathy is of value.
Many clinical studies conducted in Europe show that Flavay® greatly
improved symptoms in patients with diabetic retinopathies and maculopathies.
In one study of 26 diabetic ophthalmic patients, 100 to 200 mg per day
of Flavay® proved of therapeutic value in controlling vascular incidents,
which are characteristic of diabetic retinopathy. Several weeks of treatment
resulted in noteworthy improvement in vascular incidents, with reduced
microaneurisms and diminished exudations, and overall improvement in capillary
fragility. The vision of those taking Flavay® not only stopped decreasing,
but even improved. Flavay® protected cells against free radical
damage, and it sealed the microbleedings in the retina that obscure vision.
Clinical studies have conclusively demonstrated Flavay’s®
ability to stabilize microcapillaries in the retinal membranes and it
has therefore been licensed in France for treating diabetic retinopathy.
This shows that Flavay® should be part of the daily nutritional
regimen of every diabetic person.
Improving Visual Performance in the Dark
After Glare
Double-blind studies have demonstrated that Flavay® may significantly
improve visual performance in the dark after glare. In one study of 100
workers who sit in front of computer monitors or drive for a living, the
administration of 200mg per day of Flavay® enhanced visual adaptation
from bright light. This is the ability of the eyes to see well in a low-light
situation after being adjusted to bright light. In the eyes, a substance
known as rhodopsin, or visual purple, affects visual acuity in low light.
Rhodopsin is made by vitamin A and Flavay appears to enhance the speed
of rhodopsin activity, making it easier to go from high to low light.
Thus, just as Flavay® enhances the activity of vitamin C in the
body, it enhances an important function of vitamin A.
U.S. Patent No. 4,698,360
“Radical Scavenger” Effect of Flavay®
Patented and licensed in France for therapeutic uses, including retinopathies,
the U.S. Government granted Dr. Masquelier a patent on October 6, 1987
which allows his proanthocyanidins complex, now sold as Flavay®,
to be used as an antioxidant here in the United States.
"[A] method for preventing and fighting the harmful biological
effects of free radicals in the organism of warm blooded
animals and more especially human beings, namely cerebral involution,
hypoxia following atherosclerosis, cardiac or cerebral infarction,
tumour promotion, inflammation, ischaemia, alterations
of the synovial liquid, collagen degradation, among
others. The method consists in administering to said animals and
especially to human beings an amount, efficient against said effects,
of a plant extract with a proanthocyanidins content which has a
radical scavenger effect"—Dr. Jack Masquelier,
U.S. Patent No. 4,698,360.
The powerful free radical scavenging protection of Flavay® is especially
beneficial to the eyes, with its delicate microcapillaries.
Free Radicals, Cataracts and Macular
Degeneration
In the presence of oxygen, ultraviolet light generates free radicals
or precursors, and oxidative damage to lens proteins leads to increasing
opacity. In the young, repair mechanisms exist, but as we age they become
progressively less effective. It has been hypothesized, through both animal
and human studies, that oxidation is involved in all types of cataracts
and of age-related macular degeneration. A number of epidemiologic studies
have found that age-related eye diseases consumed significantly less antioxidants,
particularly vitamin C, than did persons who did not develop those eye
conditions. Research shows that Flavay® dramatically extends the
lifetime of vitamin C in the body, Flavay® provides its own powerful
antioxidant protection to the eyes and its tiny blood vessels, and Flavay®
enhances the protective effect of alpha-tocopherol (vitamin E) in the
eye and retina.
Best Protection for the Health of Your
Eyes and Retinas
Flavay®
is the actual product that has been licensed and sold in France for protection
against diabetic retinopathy. As shown above, Flavay® can protect
the eyes from free radical damage, support overall circulatory function,
reinforce collagen structures of the retina, enhance the eye’s ability
to visually adapt to different light environments, and protect the health
of the eye and retina.
REFERENCES:
Masquelier, J. Plant extract with
a proanthocyanidins content as a therapeutic agent having radical scavenging
effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and pycnogenol. Alfa Omega Editrice,
Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers,
1995.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing,
Inc., 1997.
Packer, L.,, et al. Antioxidant food supplements in human health. Academic
Press, 1999.
Mindell, E., et al. Earl Mindell’s vitamin bible for the 21st century.
Warner Books, Inc., 1999.
Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats
Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from Vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the
action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres procyanidoliques.
Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des
oligomeres procyanidoliques sur des cellules mesenchymateuses en culture.
Ii l’attachment des fibres elastiques aux cellules. (Study of the effect
of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment
of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal
structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’,
4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its
heterocyclic ring conformation in solution and the solid state. Journal
of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals.
Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and
b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990.
pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different procyanidins
from grape seeds. Presented at a symposium, “Free radicals in biotechnology
and medicine.” Royal Society Of Chemistry, London January 1990, pp.
79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften”
Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation
and characterization of endothelium-dependent vasorelaxing compounds from
grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium,
and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent
vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol
1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing
activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin
becomes resistant to the action of mammalian collagenase. Experientia, 37:
221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding
of pycnogenol to elastin affects its rate of degradation by elastases.
Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted
from ‘vitus vinifera l.’ in the rat. European Journal of Drug
Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity
of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo
and in vitro study. Cosmetology Department & S Biovectors, Ramonville
St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting
enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica,
May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation.
Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire,
spontanement ou artificiellement diminuee par l’action d’une substance
capillaro-toxique chez des personnes agees--action benefique d’un agnet
actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980.
pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un
microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets des oligomeres
du procyanidol sur las resistance capillaire dand l’hypertension arterielle
et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur peripherique,
l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24,
1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice
de fragilite capillaire dan une population specifique: les sujets cirrhotiques.
Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs
par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance
veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981.
pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand les manifestations
fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une
etude en double aveugle portant sur 92 patients.” Gazette Medicale,
(92)1, 1985. pp. 96-100.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate
metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty
Acids, 38:181-8, 1989.
Masquelier, J. pycnogenol: recent advances in the therapeutical activity
of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant
Research and Journal of Natural Products, July 1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications
in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires” unpub. bulletin
from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and atherothrombosis.
Office International Vigne et du Vin, Nutrition and Health Unit, Paris France;
Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131),
1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin. Acta Physiologica
Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie. Essai
Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye.
Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+)
-catechin becomes resistant to the action of mammalian collagenase.”
Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col.
of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres
procyanidoliques sur le lathyrisme experimental chez le rat.” Ann.
Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation.
Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol,
(11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling:
use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4,
177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers
effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93,
1988.
Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453,
1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C. Bordeaux Medicale,
(16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology. Bull
Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de
la fragilite capillaire et de la retinopathie chez les diabetiques. A propos
de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind
study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5,
1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in
rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica,
9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser
Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur l’ulcere gastrique. Resultats,
p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by flavonoids
and bioflavonoids. Planta Medica, 5116-20, 1985.
Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley
& Sons, Inc., 1999.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports
People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet
Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members
superieurs. Symposium Satellite, Congres International d’Angiologie,
Toulouse, France, 4-7 Oct. 1989.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques
sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux,
1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation
de l’acide ascorbique par les ions cuivriques. Bull. de la Societe
de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide
ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4)
1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka,
I. “Inhibitory effects of tannins on hyaluronidase activation and on
the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull.
33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J. “Histamine
and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress
ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase
in vitro.” Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies
chez le sportif: essai controle de l’Endothelon.” Actualite Therapeutique
90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. “Flavonoids et pycnogenol” Int J Vit Nut
Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol.
25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells
of the mouse with Pycnogenol. Cytotest Cell Research GmbH & Co., projects
143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover,
Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable
extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux,
129:51-65, 1990.
